Profile data is unavailable for this security.
About the company
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
- Revenue in USD (TTM)0.00
- Net income in USD-45.08m
- Incorporated2005
- Employees42.00
- LocationLarimar Therapeutics IncTHREE BALA PLAZA EAST. SUITE 506BALA CYNWYD 19004United StatesUSA
- Phone+1 (617) 622-4003
- Fax+1 (302) 655-5049
- Websitehttps://larimartx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 483.04m | 19.00 | -- | 4.90 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
| Applied Therapeutics Inc | -477.00k | -193.56m | 484.49m | 26.00 | -- | 7.20 | -- | -- | -1.91 | -1.91 | -0.005 | 0.589 | -0.0053 | -- | -- | -19,080.00 | -213.60 | -140.37 | -604.11 | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -108.30m | 489.81m | 118.00 | -- | 4.53 | -- | -- | -3.14 | -3.14 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -68.23 | -33.56 | -75.55 | -36.55 | -- | -- | -- | -941.88 | -- | -- | 0.00 | -- | -- | -- | -12.83 | -- | -3.47 | -- |
| Tscan Therapeutics Inc | 14.81m | -96.80m | 490.57m | 161.00 | -- | 3.62 | -- | 33.12 | -1.28 | -1.28 | 0.1784 | 2.57 | 0.0715 | -- | -- | 96,181.82 | -46.72 | -- | -52.48 | -- | -- | -- | -653.50 | -- | -- | -- | 0.1974 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -69.42m | 494.18m | 58.00 | -- | 2.70 | -- | -- | -2.71 | -2.71 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -47.71 | -- | -54.30 | -- | -- | -- | -- | -- | -- | -- | 0.0091 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| IGM Biosciences Inc | 2.11m | -236.92m | 496.39m | 216.00 | -- | 3.07 | -- | 235.81 | -4.31 | -4.31 | 0.0375 | 2.74 | 0.005 | -- | -- | 9,397.32 | -56.49 | -44.66 | -62.57 | -48.20 | -- | -- | -11,255.25 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Travere Therapeutics Inc | 155.72m | -415.73m | 503.21m | 380.00 | -- | 6.79 | -- | 3.23 | -5.32 | -2.00 | 2.04 | 0.9732 | 0.2116 | 1.57 | 7.04 | 409,800.00 | -56.49 | -36.95 | -71.19 | -44.77 | 94.34 | 95.92 | -266.96 | -165.79 | 2.75 | -- | 0.836 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Larimar Therapeutics Inc | 0.00 | -45.08m | 503.40m | 42.00 | -- | 2.18 | -- | -- | -0.9666 | -0.9666 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -24.56 | -42.22 | -26.04 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
| Astria Therapeutics Inc | 0.00 | -81.63m | 505.20m | 59.00 | -- | 1.85 | -- | -- | -2.32 | -2.32 | 0.00 | 6.70 | 0.00 | -- | -- | 0.00 | -27.34 | -64.48 | -28.18 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| OmniAB Inc | 21.05m | -63.48m | 508.10m | 106.00 | -- | 1.68 | -- | 24.14 | -0.634 | -0.634 | 0.2103 | 2.57 | 0.055 | -- | 7.18 | 198,547.20 | -16.58 | -- | -17.48 | -- | -- | -- | -301.63 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Adaptive Biotechnologies Corp | 174.50m | -215.06m | 514.32m | 709.00 | -- | 1.87 | -- | 2.95 | -1.48 | -1.48 | 1.20 | 1.87 | 0.2472 | 4.52 | 4.78 | 246,124.10 | -30.48 | -19.69 | -34.73 | -22.06 | 57.06 | 67.18 | -123.29 | -122.27 | 4.35 | -- | 0.00 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Celcuity Inc | 0.00 | -73.45m | 515.61m | 55.00 | -- | 3.80 | -- | -- | -2.79 | -2.79 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -41.61 | -37.32 | -44.44 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2193 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Heron Therapeutics Inc | 132.10m | -80.95m | 518.25m | 126.00 | -- | -- | -- | 3.92 | -0.6156 | -0.6156 | 0.9316 | -0.2245 | 0.6021 | 1.20 | 2.26 | 1,048,405.00 | -36.90 | -53.55 | -56.71 | -71.24 | 57.08 | 52.52 | -61.28 | -170.12 | 1.90 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Alector Inc | 96.41m | -120.61m | 519.51m | 244.00 | -- | 2.90 | -- | 5.39 | -1.39 | -1.39 | 1.12 | 1.86 | 0.1393 | -- | -- | 395,106.60 | -17.43 | -20.00 | -21.55 | -23.81 | -- | -- | -125.11 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Olema Pharmaceuticals Inc | 0.00 | -99.34m | 523.54m | 75.00 | -- | 2.21 | -- | -- | -2.02 | -2.02 | 0.00 | 4.23 | 0.00 | -- | -- | 0.00 | -43.24 | -30.06 | -48.01 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
Data as of May 22 2024. Currency figures normalised to Larimar Therapeutics Inc's reporting currency: US Dollar USD
37.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Mar 2024 | 6.05m | 9.48% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 4.02m | 6.30% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 3.42m | 5.36% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.34m | 3.66% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.19m | 3.43% |
| Verition Fund Management LLCas of 31 Mar 2024 | 1.50m | 2.35% |
| Adage Capital Management LPas of 31 Mar 2024 | 1.43m | 2.25% |
| Woodline Partners LPas of 31 Mar 2024 | 1.15m | 1.80% |
| Driehaus Capital Management LLCas of 31 Mar 2024 | 1.09m | 1.71% |
| Fred Alger Management LLCas of 31 Mar 2024 | 987.93k | 1.55% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
